Control group
Advagraf™ will not be provided by the sponsor, but supplied/prescribed as per site routine (Table IMP-characteristics of Advagraf™Advagraf™ therapy should commence at a starting dose of 0.1–0.2 mg/kg/day.In case the patient initially received an oral formulation of Prograf® during the run-in phase (e.g. administered via nasogastric tubing), conversion should be performed on a 1:1 (mg to mg) total daily dose basis. In case the patient initially received intravenous Prograf® therapy (continuous 24-h infusion) during the run-in phase at a dose approximately 1/5th of the recommended oral dose, the conversion to Advagraf™ should be modified accordingly.